Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis
The incidence of multidrug-resistant tuberculosis (MDR-TB) is increasing in high human immunodeficiency virus (HIV) prevalence settings, with high associated mortality. Treatment outcomes in HIV-co-infected adults and children are poorly documented. To systematically assess treatment outcomes among...
Uložené v:
| Vydané v: | The international journal of tuberculosis and lung disease Ročník 19; číslo 8; s. 969 |
|---|---|
| Hlavní autori: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
France
01.08.2015
|
| Predmet: | |
| ISSN: | 1815-7920, 1815-7920 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | The incidence of multidrug-resistant tuberculosis (MDR-TB) is increasing in high human immunodeficiency virus (HIV) prevalence settings, with high associated mortality. Treatment outcomes in HIV-co-infected adults and children are poorly documented.
To systematically assess treatment outcomes among HIV-MDR-TB co-infected patients.
We searched two databases and the proceedings of an annual international conference up to November 2014 for studies reporting on major clinical outcomes among HIV-MDR-TB-co-infected adults and children, and pooled the results using random-effects meta-analysis.
Of 4812 abstracts and articles screened, 30 studies providing data on 2578 adults and 147 children were included. Overall pooled treatment success was 56.9% (95% confidence interval [CI] 46.2-67.6), 49.9% (95%CI 38.5-61.2) among adults and 83.4% (95%CI 74.7-92) among children. Mortality was 38% in adults (95%CI 28-48.1) and 11.4% (95%CI 5.8-17.1) in children. Loss to follow-up was higher among adults (16.1%, 95%CI 9-23.2) than among children (3.9%, 95%CI 0.9-6.9). Adverse events were experienced by the majority of patients; however, this was inconsistently documented. The use of fluoroquinolones, aminoglycosides and Group IV drugs appeared to be associated with treatment success.
The proportion of HIV-MDR-TB-co-infected patients achieving treatment success was similar to success rates reported among MDR-TB patients in general, regardless of HIV status; however, mortality was higher, particularly among adults, highlighting the need for early diagnosis and more effective treatment regimens. |
|---|---|
| AbstractList | The incidence of multidrug-resistant tuberculosis (MDR-TB) is increasing in high human immunodeficiency virus (HIV) prevalence settings, with high associated mortality. Treatment outcomes in HIV-co-infected adults and children are poorly documented.
To systematically assess treatment outcomes among HIV-MDR-TB co-infected patients.
We searched two databases and the proceedings of an annual international conference up to November 2014 for studies reporting on major clinical outcomes among HIV-MDR-TB-co-infected adults and children, and pooled the results using random-effects meta-analysis.
Of 4812 abstracts and articles screened, 30 studies providing data on 2578 adults and 147 children were included. Overall pooled treatment success was 56.9% (95% confidence interval [CI] 46.2-67.6), 49.9% (95%CI 38.5-61.2) among adults and 83.4% (95%CI 74.7-92) among children. Mortality was 38% in adults (95%CI 28-48.1) and 11.4% (95%CI 5.8-17.1) in children. Loss to follow-up was higher among adults (16.1%, 95%CI 9-23.2) than among children (3.9%, 95%CI 0.9-6.9). Adverse events were experienced by the majority of patients; however, this was inconsistently documented. The use of fluoroquinolones, aminoglycosides and Group IV drugs appeared to be associated with treatment success.
The proportion of HIV-MDR-TB-co-infected patients achieving treatment success was similar to success rates reported among MDR-TB patients in general, regardless of HIV status; however, mortality was higher, particularly among adults, highlighting the need for early diagnosis and more effective treatment regimens. The incidence of multidrug-resistant tuberculosis (MDR-TB) is increasing in high human immunodeficiency virus (HIV) prevalence settings, with high associated mortality. Treatment outcomes in HIV-co-infected adults and children are poorly documented.BACKGROUNDThe incidence of multidrug-resistant tuberculosis (MDR-TB) is increasing in high human immunodeficiency virus (HIV) prevalence settings, with high associated mortality. Treatment outcomes in HIV-co-infected adults and children are poorly documented.To systematically assess treatment outcomes among HIV-MDR-TB co-infected patients.OBJECTIVETo systematically assess treatment outcomes among HIV-MDR-TB co-infected patients.We searched two databases and the proceedings of an annual international conference up to November 2014 for studies reporting on major clinical outcomes among HIV-MDR-TB-co-infected adults and children, and pooled the results using random-effects meta-analysis.METHODSWe searched two databases and the proceedings of an annual international conference up to November 2014 for studies reporting on major clinical outcomes among HIV-MDR-TB-co-infected adults and children, and pooled the results using random-effects meta-analysis.Of 4812 abstracts and articles screened, 30 studies providing data on 2578 adults and 147 children were included. Overall pooled treatment success was 56.9% (95% confidence interval [CI] 46.2-67.6), 49.9% (95%CI 38.5-61.2) among adults and 83.4% (95%CI 74.7-92) among children. Mortality was 38% in adults (95%CI 28-48.1) and 11.4% (95%CI 5.8-17.1) in children. Loss to follow-up was higher among adults (16.1%, 95%CI 9-23.2) than among children (3.9%, 95%CI 0.9-6.9). Adverse events were experienced by the majority of patients; however, this was inconsistently documented. The use of fluoroquinolones, aminoglycosides and Group IV drugs appeared to be associated with treatment success.RESULTSOf 4812 abstracts and articles screened, 30 studies providing data on 2578 adults and 147 children were included. Overall pooled treatment success was 56.9% (95% confidence interval [CI] 46.2-67.6), 49.9% (95%CI 38.5-61.2) among adults and 83.4% (95%CI 74.7-92) among children. Mortality was 38% in adults (95%CI 28-48.1) and 11.4% (95%CI 5.8-17.1) in children. Loss to follow-up was higher among adults (16.1%, 95%CI 9-23.2) than among children (3.9%, 95%CI 0.9-6.9). Adverse events were experienced by the majority of patients; however, this was inconsistently documented. The use of fluoroquinolones, aminoglycosides and Group IV drugs appeared to be associated with treatment success.The proportion of HIV-MDR-TB-co-infected patients achieving treatment success was similar to success rates reported among MDR-TB patients in general, regardless of HIV status; however, mortality was higher, particularly among adults, highlighting the need for early diagnosis and more effective treatment regimens.CONCLUSIONThe proportion of HIV-MDR-TB-co-infected patients achieving treatment success was similar to success rates reported among MDR-TB patients in general, regardless of HIV status; however, mortality was higher, particularly among adults, highlighting the need for early diagnosis and more effective treatment regimens. |
| Author | Tseretopoulou, X Ntzani, E E Isaakidis, P Ford, N Das, M Casas, E C |
| Author_xml | – sequence: 1 givenname: P surname: Isaakidis fullname: Isaakidis, P organization: Médecins Sans Frontières, Mumbai, India; Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece – sequence: 2 givenname: E C surname: Casas fullname: Casas, E C organization: Operational Center Amsterdam, Médecins Sans Frontières, Amsterdam, The Netherlands – sequence: 3 givenname: M surname: Das fullname: Das, M organization: Médecins Sans Frontières, Mumbai, India – sequence: 4 givenname: X surname: Tseretopoulou fullname: Tseretopoulou, X organization: Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece – sequence: 5 givenname: E E surname: Ntzani fullname: Ntzani, E E organization: Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece – sequence: 6 givenname: N surname: Ford fullname: Ford, N organization: Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26162364$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkM1LwzAchoNM3IcevUqOXjqTtElTbzo_NpgIMr2WNP0FM5p0NqnS_16ZEzy9LzwP7-GdopFvPSB0Tsmccymv7DY29ZzyOaEsPUITKilP8oKR0b8-RtMQtoQwSml-gsZMUMFSkU3QdtOBig58xG0fdesgYNN2eLl6w8rX-OnuJdncYt0m1hvQEWqs6r6JYU_1u23qDvw1DkOI4FS0GnfwaeFrzx1ElSivmiHYcIqOjWoCnB1yhl4f7jeLZbJ-flwtbtaJzgSNiZSU1YQTkGlRKcFETpSQlTCccV5lklUauORAOHBmaCEKCSyTWlTKFEYoNkOXv7u7rv3oIcTS2aChaZSHtg8lFQXPeZ7S7Ee9OKh95aAud511qhvKv3_YN0bVaPY |
| CitedBy_id | crossref_primary_10_1183_13993003_02363_2016 crossref_primary_10_1177_2050313X211019790 crossref_primary_10_1186_s41256_016_0010_y crossref_primary_10_1007_s00408_016_9860_9 crossref_primary_10_1007_s11904_022_00641_x crossref_primary_10_1136_bmjresp_2017_000256 crossref_primary_10_7759_cureus_35154 crossref_primary_10_1177_09622802211046383 crossref_primary_10_1093_cid_ciy1105 crossref_primary_10_1016_j_ijid_2017_01_038 crossref_primary_10_1371_journal_pone_0147397 crossref_primary_10_1371_journal_pone_0193491 crossref_primary_10_1016_j_ijid_2020_03_064 crossref_primary_10_1080_17476348_2021_1921577 crossref_primary_10_1080_16549716_2017_1290317 crossref_primary_10_1186_s12879_019_4317_4 crossref_primary_10_1371_journal_pone_0205601 crossref_primary_10_1186_s12879_017_2655_7 crossref_primary_10_3389_fmed_2023_1136094 crossref_primary_10_1016_S0140_6736_15_00319_0 crossref_primary_10_1111_hiv_13163 crossref_primary_10_1093_cid_cix422 crossref_primary_10_1186_s13690_021_00713_1 crossref_primary_10_3389_fmed_2023_1292665 crossref_primary_10_1097_QAI_0000000000002190 crossref_primary_10_1371_journal_pone_0197145 crossref_primary_10_1371_journal_pone_0209932 crossref_primary_10_3389_fped_2019_00159 crossref_primary_10_1007_s15010_017_1054_8 crossref_primary_10_21292_2075_1230_2021_99_2_45_51 crossref_primary_10_1016_j_ijtb_2025_08_006 crossref_primary_10_1155_2017_6232071 crossref_primary_10_1371_journal_pone_0261149 crossref_primary_10_1371_journal_pone_0187223 crossref_primary_10_1080_14740338_2016_1216544 crossref_primary_10_21292_2075_1230_2021_99_10_40_45 crossref_primary_10_1016_j_ijtb_2017_08_027 crossref_primary_10_1186_s41479_016_0021_y crossref_primary_10_1371_journal_pone_0142873 crossref_primary_10_1016_j_tim_2020_03_015 crossref_primary_10_1371_journal_pone_0246284 crossref_primary_10_7759_cureus_37033 crossref_primary_10_1080_14656566_2017_1373090 crossref_primary_10_1128_microbiolspec_TBTB2_0012_2016 crossref_primary_10_1093_cid_cix1125 crossref_primary_10_7448_IAS_18_7_20236 crossref_primary_10_1016_j_jinf_2017_10_007 crossref_primary_10_1007_s40506_018_0145_0 crossref_primary_10_1183_13993003_00353_2018 crossref_primary_10_1186_s12879_016_1524_0 crossref_primary_10_3390_v17010127 crossref_primary_10_1016_j_phrs_2022_106336 crossref_primary_10_1186_s13256_022_03436_1 crossref_primary_10_1097_COH_0000000000000499 crossref_primary_10_1001_jamanetworkopen_2022_16527 crossref_primary_10_1186_s13063_023_07520_9 crossref_primary_10_1016_S2213_2600_17_30079_6 crossref_primary_10_1155_2019_3569018 crossref_primary_10_1186_s12879_021_06801_5 crossref_primary_10_22625_2072_6732_2025_17_1_26_35 crossref_primary_10_1016_j_ijregi_2023_11_004 crossref_primary_10_1097_INF_0000000000001691 crossref_primary_10_1371_journal_pone_0248174 crossref_primary_10_1186_s12916_020_01626_6 crossref_primary_10_7448_IAS_18_7_20770 crossref_primary_10_1164_rccm_201909_1874ST crossref_primary_10_1080_17476348_2021_1828069 crossref_primary_10_21292_2075_1230_2020_98_5_44_50 crossref_primary_10_1186_s40794_018_0065_5 crossref_primary_10_1016_S2352_3018_16_00002_3 crossref_primary_10_1097_COH_0000000000000303 crossref_primary_10_1371_journal_pone_0312698 crossref_primary_10_1097_QAI_0000000000001169 crossref_primary_10_1371_journal_pone_0204982 crossref_primary_10_1016_j_micinf_2022_105020 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.5588/ijtld.15.0123 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1815-7920 |
| ExternalDocumentID | 26162364 |
| Genre | Meta-Analysis Systematic Review Journal Article |
| GroupedDBID | --- ..I 0VX 29J 2WC 53G 5GY 5RE ACGFO ACPRK ADBBV AENEX AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL CGR CUY CVF DIK DU5 EBS ECM EIF EJD F5P H13 IPNFZ J8S NPM OK1 P2P PQQKQ RIG TR2 YHZ 7X8 |
| ID | FETCH-LOGICAL-c461t-8812d050e839ba62670a68b6f5255b482bce585e05e52f19698e248c6baf9f6a2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 93 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000358553100017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1815-7920 |
| IngestDate | Sun Nov 09 10:37:54 EST 2025 Sun Jul 13 01:33:41 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c461t-8812d050e839ba62670a68b6f5255b482bce585e05e52f19698e248c6baf9f6a2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4 |
| PMID | 26162364 |
| PQID | 1695757314 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1695757314 pubmed_primary_26162364 |
| PublicationCentury | 2000 |
| PublicationDate | 2015-Aug 20150801 |
| PublicationDateYYYYMMDD | 2015-08-01 |
| PublicationDate_xml | – month: 08 year: 2015 text: 2015-Aug |
| PublicationDecade | 2010 |
| PublicationPlace | France |
| PublicationPlace_xml | – name: France |
| PublicationTitle | The international journal of tuberculosis and lung disease |
| PublicationTitleAlternate | Int J Tuberc Lung Dis |
| PublicationYear | 2015 |
| References | 26162350 - Int J Tuberc Lung Dis. 2015 Aug;19(8):877-8. doi: 10.5588/ijtld.15.0458. |
| References_xml | – reference: 26162350 - Int J Tuberc Lung Dis. 2015 Aug;19(8):877-8. doi: 10.5588/ijtld.15.0458. |
| SSID | ssj0021117 |
| Score | 2.4445732 |
| SecondaryResourceType | review_article |
| Snippet | The incidence of multidrug-resistant tuberculosis (MDR-TB) is increasing in high human immunodeficiency virus (HIV) prevalence settings, with high associated... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 969 |
| SubjectTerms | Adult Age Factors Anti-HIV Agents - therapeutic use Antitubercular Agents - adverse effects Antitubercular Agents - therapeutic use Child HIV Infections - drug therapy HIV Infections - epidemiology Humans Incidence Treatment Outcome Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - epidemiology Tuberculosis, Multidrug-Resistant - mortality |
| Title | Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/26162364 https://www.proquest.com/docview/1695757314 |
| Volume | 19 |
| WOSCitedRecordID | wos000358553100017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwFA7qRHzxfpk3Ivga7SVNE1_E25jgxpApextpegob2k7b-fs96UWfBMGXvoSWkp7mfF_Ol-8QciZVZPOUy8LIF4wHBpjWvs8UKF9HSps4Lk1cH8N-X45GalBvuOW1rLJZE8uFOs6M3SO_cIVCZBH6Lr-avTPbNcpWV-sWGouk5SOUsZKucPRdRUBuU3bcxSRmbRk9p_LYDAIkfZNp8Rqfu9az03Yq-g1dllmms_7f99sgazW-pNdVQGySBUi3yEqvrqBvk-mwUZbTbF7goyGniFtp9-GF6jSmvbsnNryhJmOVTAtiWlp05OVoc_T7kv44QNPq9Es5_gaFZrr2Odkhz5374W2X1f0WmOHCLZjEZB87gQMImiKNTCd0tJCRSALkHRGXXmQA2QU4AQReYn11JHhcGhHpRCVCe7tkKc1S2CfUdX1uEnCNso6H0kgARyaKg1Q65DG0yWkzi2OMZ1uk0Clk83z8M49tsld9ivGsMt4YI9sT1vD-4A93H5JVxDZBpdU7Iq0E_2Y4Jsvms5jkHydloOC1P-h9AcR8yGg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+outcomes+for+HIV+and+MDR-TB+co-infected+adults+and+children%3A+systematic+review+and+meta-analysis&rft.jtitle=The+international+journal+of+tuberculosis+and+lung+disease&rft.au=Isaakidis%2C+P&rft.au=Casas%2C+E+C&rft.au=Das%2C+M&rft.au=Tseretopoulou%2C+X&rft.date=2015-08-01&rft.eissn=1815-7920&rft.volume=19&rft.issue=8&rft.spage=969&rft_id=info:doi/10.5588%2Fijtld.15.0123&rft_id=info%3Apmid%2F26162364&rft_id=info%3Apmid%2F26162364&rft.externalDocID=26162364 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1815-7920&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1815-7920&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1815-7920&client=summon |